Successful treatment with quetiapine for delirium in terminally ill cancer patients

Psychogeriatrics

Volumn 7, Issue 2, 2007, Pages 64-68

  Shinno, Hideto ^a,b,c   Matsuoka, Tatsuo ^a   Yamamoto, Osamu ^a   Noma, Yoko ^a   Hikasa, Satoshi ^a   Takebayashi, Minoru ^a   Horiguchi, Jun ^b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c NONE   (Japan)

Author keywords

Atypical neuroleptics; Delirium; MDAS; Quetiapine; Terminal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; HALOPERIDOL; MORPHINE; NEUROLEPTIC AGENT; QUETIAPINE;

ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PAIN; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; DELIRIUM; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LABORATORY TEST; LIVER CANCER; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RIGIDITY; SEDATION; SIDE EFFECT; SLEEP AROUSAL DISORDER; STOMACH CARCINOMA; SYMPTOM; TERMINALLY ILL PATIENT; UNSPECIFIED SIDE EFFECT;

EID: 34249982606     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2007.00182.x     Document Type: Article

References (17)

1. Minagawa H, Uchitomi Y, Yamawaki S, Ishitani K. Psychiatric morbidity in terminally ill cancer patients. A prospective study. Cancer 1996; 78: 1131-1137.
2. American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999; 156: 1-20.
3. Sipahimalani A, Sime RM, Masand PS. Treatment of delirium with risperidone. Int J Geriatr Psychopharmacol 1997; 1: 24-26.
4. Horikawa N, Yamazaki T, Miyamoto K et al. Treatment of delirium with risperidone: Results of a prospective open trial with 10 patients. Gen Hosp Psychiatry 2003; 25: 289-292.
5. Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics 1998; 39: 422-430.
6. Breibart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 2002; 43: 175-182.
7. Schwartz TL, Masand PS. Treatment of delirium with quetiapine. Primary Care Companion J Clin Psychiatry 2000; 2: 10-12.
8. Sasaki Y, Matsuyama T, Inoue S et al. A prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. J Clin Psychiatry 2003; 64: 1316-1321.
9. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
10. Matsuoka Y, Miyake Y, Arakaki H, Tanaka K, Saeki T, Yamawaki S. Clinical utility and validation of the Japanese version of Memorial Delirium Assessment Scale in a psychogeriatric inpatient setting. Gen Hosp Psychiatry 2001; 23: 36-40.
11. Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry 2003; 25: 345-352.
12. Seeman P. Atypical antipsychotics: Mechanisms of action. Can J Psychiatry 2002; 47: 27-38.
13. Idzikowski C, Mills FJ, Glennard R. 5-hydroxytryptamine-2-antagonist increases human slow wave sleep. Brain Res 1986; 378: 164-168.
14. Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002; 43: 171-174.
15. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65: 5-99.
16. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet 2001; 40: 509-522.
17. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The memorial delirium assessment scale. J Pain Symptom Manage 1997; 13: 128-137.